Non-invasive prenatal testing (NIPT) has been garnering higher adoption especially in the cases of high risk pregnant women. Chromosomal disorders such as Edwards syndrome, down syndrome, Turner syndrome, and Patau syndrome are some of the diseases that can be screened using non-invasive prenatal testing. Gynecologists and pregnant women prefer the safety, non-invasiveness, and accuracy of non-invasive prenatal testing technology, although there are other testing techniques available such as amniocentesis and chorionic villus sampling. In October 2011, the premier non-invasive prenatal testing technology was launched by Sequenom, Inc., a U.S.- based a leading provider of extremely sensitive laboratory tests and innovator in the domain of molecular technology. The company held the leading position in the market by volume as well as revenue.

In 2013, the global non-invasive prenatal testing market was pegged that US$0.5 bn. The global NIPT market is expected to obtain a revenue worth US$2.38 bn by 2022, advancing rapidly at a phenomenal CAGR of 17.50% between 2014 and 2022.

High Prevalence of Chromosomal Disorders in Europe to Amp up Growth

By geography, Latin America, the Middle East and Africa, North America, Asia Pacific, and Europe can be the key segments of the global market for non-invasive prenatal testing. Of these, North America accounted for a volume of 51.0% and revenue of 58.8% in the global market for non-invasive prenatal testing market in 2013. The U.S. has been responsible for the growth of the segment due to the presence of several significant market players in the region. The findings of Down Syndrome Education (DSE), the frequency of Down Syndrome in the U.S. has been rising at a fast pace, leading to 4,700 cases on an annual basis, reflected in almost one in about 830 births in the U.S.

The prevalence of the condition is even higher in the European countries. It was found that one in every 920 newborns was diagnosed with Down syndrome. Because traditional testing methods such as chorionic villus sampling and amniocentesis can lead to miscarriage, the non-invasive prenatal testing technology is being increasingly recognized as a safe technique. The advancement of non-invasive prenatal tests enables an assessment of cell-free DANA that float in maternal plasma, thereby posing no risk of miscarriage.

The non-invasive prenatal testing market in Asia Pacific has been prognosticated to gain a large revenue in the global market, representing a vast chunk of the total market. The trend of late pregnancy has been leading to a growing incidence of complications among expecting mothers. This has been one of the basic propellants of the non-invasive prenatal testing market in the region. China, Australia, India and Japan are likely to surface as major contributors to the market's growth.

MaterniT20 PLUS Held Largest Share in Global Non-invasive Prenatal Testing Market in 2013

The global market for non-invasive prenatal testing can be segmented by the type of tests too. VisibiliT, informaSeq, MaterniT20 PLUS, NIFTY, BambniTest, verifi, Harmony, PrenaTest, and Panorama are some of the key segments of the global market for non-invasive prenatal testing. During 2013 the MaterniT20 PLUS segment held a share of 36.1% of the overall market for NIPT. However, over the oncoming period, the NIFTY, Panorama, Bambni, and Verifi are slated to advance at a greater pace, waiting in the wings to replace the MaterniT20 PLUS market segment.

Over the decade, the global non-invasive prenatal testing (NIPT) has shown a healthy growth. The rise in the global average of maternal age, coupled with the increasing incidence of Down syndrome in newborns, has boosted the market to a significant level. Additionally, the augmenting demand for timely and non-invasive fetal diagnosis is anticipated to propel the market in the coming years.

The global NIPT market is analyzed on the basis of the tests and the regional distribution of this market. Based on tests, the market is broadly classified into BambniTest, informaSeq, Harmony, MaterniT21 PLUS, Panorama, NIFTY, PrenaTest, VisibiliT, and verifi. Regionally, the worldwide market for NIPT is distributed among North America, Asia Pacific, Europe, and the Rest of the World.

The report present a comprehensive study of the global NIPT market with an analytical approach. Market drivers, restraints, opportunities, current and upcoming trends, and various segmentations of this market has been discussed at length in this study, making it a valuable source of guidance for market participants.

Overview of the Global NIPT Market

The global NIPT market stood at US$0.5 bn in 2013. Expanding at a CAGR of 17.50% over the period from 2014 to 2022, the market is projected to reach US$2.38 bn by the end of the forecast period.

According to the report, the first non-invasive prenatal test launched in the market was MaterniT21 PLUS. The test was introduced in 2011 and was intended to diagnose trisomy 21. In 2013, the market for MaterniT21 PLUS accounted for 36.1% of the total revenue generated in the NIPT market across the globe. However, this market segment is likely to lose ground on account of rising commercialization of panorama, Verifi, Bambni, and NIFTY during the forecast period.

The NIPT market in North America emerged as the largest regional market of the global NIPT market in 2013 with a 58.8% share in terms of revenue and a 51% share in terms of volume. The presence of major market participants in the U.S. and a high level of awareness pertaining to NIPT in North America has boosted the regional market extensively.

The Asia Pacific NIPT market is showing immense potential for growth. Australia, Japan, India, and China are the key markets for NIPT in this region. A large population base of women choosing late pregnancy is expected to drive the Asia Pacific market for NIPT market over the forecast period.

The presence of untapped opportunities in developing economies across the globe provides a huge potential market for participants. However, the strict regulatory guidelines regarding non-invasive prenatal testing and the availability of alternative screening and testing procedures are likely inhibit the growth of the market to an extent.

Companies mentioned in the research report

Laboratory Corporation of America Holdings, Berry Genomics Co. Ltd., Illumina Inc., LifeCodexx AG, Sequenom Inc., BGI Diagnostics, Ariosa Diagnostics Inc., and Natera Inc. are the major companies functioning in the global NIPT market. Strategic partnership and alliance with hospitals, medical research centers, and clinical laboratories are the key trends among the market participants for the expansion of their business.

Upcoming Reports

Robotic surgery, also known as robot assisted surgery, is an emerging advanced medical technology which helps specialist surgeons perform many types of complex procedures with more accuracy, control, and flexibility as compared to the conventional pr...

Aortic aneurysm is widening of the aorta (the largest artery in the human body) at a certain spot, which can potentially rupture the artery. The abdominal aorta is generally observed to have the maximum diameter of >3 cm.
...

Safety heelstick is a consistent, safe, and precise heel incision device specifically designed for infants. The heel incision device provides a safe and effective means for obtaining blood samples from the heels of newborns.
...

Pannus is a layer of fibrovascular tissue that abnormally outspreads the surface of an organ. It is generally referred as abdominal granular fatty tissue, hanging below the abdominal area in case of obese people; however, on a broader scale, the term...

Tracheostomy is a surgical procedure performed to create a surgical airway in the trachea. Various disease conditions such as difficulty in breathing, neurological trauma, and infectious or chronic airway diseases require a tracheostomy procedure to ...